Inhibrx's Experimental Cancer Therapy Outperforms Merck's Keytruda in Trial Data
Inhibrx Biosciences (INBX) reported that its experimental therapy, INBRX-106, outperformed Merck’s (MRK:NYSE) leading cancer drug Keytruda in treating head and neck cancers. The data comes from the Phase 2 portion of a clinical trial and has led to an increase in Inhibrx's stock price ahead of market open on Tuesday. The results suggest that INBRX-106 could offer improved efficacy compared to pembrolizumab, Keytruda’s active ingredient. This development is significant for Inhibrx as it seeks regulatory approval and commercialization opportunities for its new therapy in a competitive oncology space dominated by Merck's product. The market reaction highlights investor interest in novel cancer treatments that show superior performance over existing standards of care.
Topics: biotech cancer therapy clinical trials